All In Biotech

NDA 019873 · B Braun

Isolyte P In Dextrose 5% In Plastic Container

Dextrose, Magnesium Chloride, Potassium Chloride, Potassium Phosphate, Dibasic, Sodium Acetate · Injection

Last checked: Nov 19, 2026Latest source record: May 11, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Jun 10, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3,797

712 Phase 3, 359 recruiting

FAERS reports

7

7 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 24, 2024.

INDICATIONS AND USAGE This solution is indicated for use in adults as a source of electrolytes, calories and water for hydration, and as an alkalinizing agent.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 10, 1993 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER · DEXTROSE 5GM/100ML; MAGNESIUM CHLORIDE 31MG/100ML; POTASSIUM CHLORIDE 130MG/100ML; POTASSIUM PHOSPHATE, DIBASIC 26MG/100ML; SODIUM ACETATE 320MG/100ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextrose" as an intervention, any sponsor and status, largest first.

All 3,797 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • alanine aminotransferase increased2
  • aspartate aminotransferase increased2
  • blood bilirubin increased2
  • drug abuse2
  • gamma-glutamyltransferase increased2
  • neuroleptic malignant syndrome2
  • off label use2
  • anaemia1
  • asthenia1
  • autoimmune hepatitis1
  • cardiac failure1
  • death1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
20162
20201
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,414 on PubMed

Sponsor: B Braun

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.